Table 1.
Baseline characteristics and demographics of randomized patients
| Variable | DU 1.5 mg (N = 304) | DU 0.75 mg (N = 302) | SITA (N = 315) | PL (N = 177) |
|---|---|---|---|---|
| Sex | ||||
| Men | 146 (48) | 134 (44) | 151 (48) | 90 (51) |
| Women | 158 (52) | 168 (56) | 164 (52) | 87 (49) |
| Age (years) | 54 ± 10 | 54 ± 10 | 54 ± 10 | 55 ± 9 |
| Race | ||||
| Aboriginal | 0 (0) | 0 (0) | 1 (<1) | 0 (0) |
| Black | 16 (5) | 12 (4) | 7 (2) | 9 (5) |
| White | 157 (52) | 162 (54) | 158 (50) | 91 (51) |
| East Asian | 50 (16) | 47 (16) | 52 (17) | 28 (16) |
| Hispanic | 54 (18) | 51 (17) | 67 (21) | 38 (22) |
| Native American | 0 (0) | 0 (0) | 1 (<1) | 0 (0) |
| West Asian | 27 (9) | 30 (10) | 28 (9) | 11 (6) |
| BMI (kg/m2) | 31 ± 5 | 31 ± 4 | 31 ± 4 | 31 ± 4 |
| Weight (kg) | 87 ± 17 | 86 ± 18 | 86 ± 17 | 87 ± 17 |
| Diabetes duration (years) | 7 ± 6 | 7 ± 5 | 7 ± 5 | 7 ± 5 |
| HbA1c [% (mmol/mol)] | 8.1 ± 1.1 (65 ± 12) | 8.2 ± 1.1 (66 ± 12) | 8.1 ± 1.1 (65 ± 12) | 8.1 ± 1.1 (65 ± 12) |
| Antihyperglycemic medicationa | ||||
| OAM | 290 (95) | 284 (94) | 294 (93) | 167 (94) |
| One medication class | 203 (67) | 193 (64) | 218 (69) | 114 (64) |
| Two medication classes | 83 (27) | 89 (30) | 76 (24) | 49 (28) |
| More than two medication classes | 4 (1) | 2 (1) | 0 (0) | 4 (2) |
| SBP (mmHg) | 129 ± 13 | 128 ± 14 | 127 ± 13 | 128 ± 13 |
| DBP (mmHg) | 78 ± 8 | 78 ± 9 | 77 ± 9 | 78 ± 8 |
Data are means ± SD or n (%) unless otherwise indicated.
DU, dulaglutide; PL, placebo; SITA, sitagliptin.
aAt screening.